Obesity is not simply an excess of weight: it is a chronic and multifactorial disease, characterized by deep metabolic disruption. It goes far beyond aesthetics. It involves constant systemic inflammation, insulin resistance, endothelial dysfunction, and a significantly increased risk of cardiovascular diseases such as heart attack, high blood pressure, heart failure, or stroke.

Effective obesity management involves more than individual willpower. Without structured and continuous support, most people who try to lose weight regain it over time. That’s why, in recent years, the development of new pharmacological treatments—such as GLP-1 analogs—has represented a major clinical breakthrough, especially in patients with high cardiovascular risk. At Clínica Samon, these medications are integrated into a multidisciplinary program in which therapeutic nutrition and structured physical exercise also play a central role.

Glucagon-like peptide-1 (GLP-1) analogs mimic an intestinal hormone that regulates appetite, gastric emptying, and insulin secretion. Among the most commonly used are semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro), the latter acting on both GLP-1 and GIP, two key hormones in metabolic control.

In clinical trials such as STEP (with semaglutide) and SURMOUNT (with tirzepatide), average reductions of 15% in body weight have been observed, along with improvements in parameters such as lipid profile, blood pressure, and blood glucose. Furthermore, semaglutide has demonstrated a reduction in cardiovascular events in people with obesity and high risk.

However, the success of an intervention cannot be measured by the scale alone. Some of the lost weight may be muscle mass, which represents an important clinical risk. Muscle loss—documented in studies using DEXA and MRI—can negatively affect strength, basal metabolism, and long-term functional capacity.

For this reason, at Clínica Samon we apply a strategy aimed at preserving or even increasing muscle mass, combining medical treatment with individualized strength training. We also prioritize the reduction of visceral fat, which is much more relevant from a cardiometabolic perspective, and we adjust the treatment to minimize side effects such as nausea, hypoglycemia, or excessive loss of appetite.

The treatment of obesity must move away from quick fixes and adopt a comprehensive approach based on three fundamental pillars:

• Personalized nutrition, with sustainable, hypocaloric, normoproteic meal plans tailored to each patient’s needs, including nutritional education.
• Structured physical exercise, combining effective aerobic and strength training, supervised by healthcare professionals.
• Individualized medical treatment, including medications such as Ozempic, Wegovy, or Mounjaro in selected patients, taking into account their clinical profile, goals, and tolerance.

Follow-up includes regular assessment of body composition, cardiovascular risk, and functionality—beyond weight alone. This approach allows for intervention not only on obesity but also on the mechanisms that sustain it and the risks it generates. Obesity is treatable and reversible, but it requires a comprehensive, person-centered medical strategy. GLP-1 analogs have proven to be a powerful tool to improve not only weight but also cardiovascular prognosis. At Clínica Samon, we use them as part of a global plan aimed at improving metabolic health, quality of life, and long-term prevention